These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 7115441)

  • 1. Effect of haloperidol pre- and post-treatment on the ability of pergolide and bromocriptine to antagonize the gamma-butyrolactone-induced increase in brain dopamine in rats.
    Fuller RW; Perry KW
    Biochem Pharmacol; 1982 Jun; 31(12):2199-200. PubMed ID: 7115441
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypophysectomy fails to affect the supersensitivity of striatal dopamine target cells induced by prolonged haloperidol treatment.
    Scatton B; Fage D
    Eur J Pharmacol; 1984 Feb; 98(1):1-7. PubMed ID: 6538845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoreceptors mediate the inhibition of dopamine synthesis by bromocriptine and lisuride in rats.
    Tissari AH; Rossetti ZL; Meloni M; Frau MI; Gessa GL
    Eur J Pharmacol; 1983 Aug; 91(4):463-8. PubMed ID: 6413231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time course of the changes in striatal acetylcholine levels induced by pergolide and haloperidol after lesion of the nigrostriatal dopaminergic pathways in the rat.
    Fage D; Guerin B; Feuerstein C; Demenge P; Scatton B
    Brain Res; 1984 Sep; 310(2):379-83. PubMed ID: 6488029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral effects of long-term neuroleptic treatment in Cebus monkeys.
    Casey DE
    Psychopharmacology Suppl; 1985; 2():211-6. PubMed ID: 3858801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevation of serum corticosterone in rats by dopamine agonists related in structure to pergolide.
    Fuller RW; Snoddy HD; Mason NR; Clemens JA; Bemis KG
    Neuroendocrinology; 1983; 36(4):285-90. PubMed ID: 6866215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential behavioral and biochemical effects of four dopaminergic agonists.
    Gianutsos G; Moore KE
    Psychopharmacology (Berl); 1980; 68(2):139-46. PubMed ID: 6107946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. d-Amphetamine and gamma-butyrolactone alteration of dopamine synthesis in the terminals of nigrostriatal and mesolimbic neurons. Possible role of various autoreceptor sensitivities.
    Demarest KT; Lawson-Wendling KL; Moore KE
    Biochem Pharmacol; 1983 Feb; 32(4):691-7. PubMed ID: 6403019
    [No Abstract]   [Full Text] [Related]  

  • 9. Attenuation by pergolide of haloperidol-induced striatal dopamine receptor density.
    Koller WC
    J Clin Psychopharmacol; 1984 Dec; 4(6):343-5. PubMed ID: 6512004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depletion of epinephrine in rat hypothalamus by a dopamine agonist, pergolide.
    Fuller RW; Perry KW; Hemrick-Luecke SK
    Neurochem Res; 1982 Apr; 7(4):399-405. PubMed ID: 6125905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the mode of action of six putative dopamine receptor agonists on suppression of exploratory behaviour in rats.
    Ståhle L; Ungerstedt U
    Psychopharmacology (Berl); 1987; 91(2):139-46. PubMed ID: 3675730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of oral pergolide mesylate on nociceptive spinal cord reflexes in rats.
    Shannon HE; Bemis KG; Peters SC
    Life Sci; 1991; 48(23):2243-8. PubMed ID: 2046457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevation of serum corticosterone concentrations in rats by pergolide and other dopamine agonists.
    Fuller RW; Snoddy HD
    Endocrinology; 1981 Oct; 109(4):1026-32. PubMed ID: 6116593
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of gamma-butyrolactone, amphetamine, and haloperidol in mice differing in sensitivity to alcohol.
    Dudek BC; Fanelli RJ
    Psychopharmacology (Berl); 1980; 68(1):89-97. PubMed ID: 6771802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central dopamine receptors mediating pergolide-induced elevation of serum corticosterone in rats. Characterization by the use of antagonists.
    Fuller RW; Snoddy HD
    Neuropharmacology; 1984 Dec; 23(12A):1389-94. PubMed ID: 6527743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two new dopamine agonists that are long acting in vivo but short acting in vitro.
    Grossman A; Yeo T; Delitala G; Hathway NR; Besser GM
    Clin Endocrinol (Oxf); 1980 Dec; 13(6):595-9. PubMed ID: 7226572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition by dopamine agonists of dopamine accumulation following gamma-hydroxybutyrate treatment.
    Handforth A; Sourkes TL
    Eur J Pharmacol; 1975 Dec; 34(2):311-9. PubMed ID: 1243993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of three dopamine agonists on cage climbing behavior.
    Gianutsos G; Palmeri JL
    Psychopharmacology (Berl); 1983; 79(4):329-31. PubMed ID: 6134299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenohypophysial dopamine content and prolactin secretion in the aged male and female rat.
    Demarest KT; Moore KE; Riegle GD
    Endocrinology; 1985 Apr; 116(4):1316-23. PubMed ID: 3971917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of pergolide on MOPEG sulphate levels in rat brain regions.
    Fuller RW; Perry KW
    J Pharm Pharmacol; 1983 Jan; 35(1):57-8. PubMed ID: 6131970
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.